U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

While first-generation glucagon-like peptide-1 receptor agonists have clearly taken the obesity market by storm, generating billions of dollars for Novo Nordisk A/S and Eli Lilly and Co., several ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don't just curb their desire to eat; for some, they also lead them to drink ...

New DTC platforms like LillyDirect and PfizerForAll are triggering a paradigm shift in how pharma companies connect with patients.

We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...

Customers are to be offered discounted weight loss treatments through insurance giant Vitality in a UK first. The group, ...

Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...

Some two years into Leqembi’s launch, Eisai continues to go all-in on its Alzheimer’s disease-fighting antibody, which the ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey ...

Discover how small biotechs are innovating in the weight loss therapy market with new treatments targeting unique mechanisms ...

Compounded semaglutide is legal, but it's not regulated in the same way as medications like Ozempic and Wegovy.